SBI Securities Co. Ltd. Reduces Holdings in Gilead Sciences, Inc. $GILD

SBI Securities Co. Ltd. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% during the second quarter, Holdings Channel reports. The firm owned 20,732 shares of the biopharmaceutical company’s stock after selling 477 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Gilead Sciences were worth $2,299,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Activest Wealth Management boosted its holdings in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. GoalVest Advisory LLC boosted its stake in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the 2nd quarter worth $27,000. Putney Financial Group LLC increased its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. Finally, Colonial Trust Advisors increased its stake in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares in the company, valued at $66,013,726.98. This trade represents a 1.66% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 71,500 shares of company stock valued at $8,336,040. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $133.00 target price on shares of Gilead Sciences in a research note on Friday, October 31st. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Morgan Stanley lifted their target price on Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Wolfe Research upped their price target on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Finally, Royal Bank Of Canada increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $128.27.

Gilead Sciences Stock Up 0.7%

Gilead Sciences stock opened at $123.40 on Thursday. The stock’s 50 day moving average price is $116.99 and its 200 day moving average price is $112.55. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.87. The company has a market cap of $153.10 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the previous year, the firm earned $2.02 EPS. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.